How to take Elafibranor-Iqirvo

Elafibranor (Elafibranor)-Iqirvo, branded as Iqirvo, is a drug used to treat primary cholangitis. It is suitable for combination treatment with ursodeoxycholic acid in adults with primary cholangitis that has a poor response to ursodeoxycholic acid, or for monotherapy in patients who cannot tolerate ursodeoxycholic acid.

Elafibranor is a dual PPARα/δ agonist whose unique molecular structure enables it to simultaneously activate three peroxisome proliferator-activated receptors: PPAR-α, PPAR-γ and PPAR-δ. This pleiotropic effect makes Elafibranor advantageous in regulating lipid metabolism, improving insulin resistance, and reducing inflammatory responses. The main active metabolite of Iqirvo, GFT1007, is also a PPAR agonist and works together with Elafibranor to exert therapeutic effects. By activating these receptors, Iqirvo may reduce the amount of bile produced by the liver, thereby relieving symptoms of primary cholangitis

Before using Iqirvo, the doctor will conduct a comprehensive evaluation of the patient, including examination for muscle pain or myopathy, to ensure that the patient is suitable for use of the drug. At the same time, for women with reproductive potential, doctors will verify that they are not pregnant to ensure the safety of the medication.

Iqirvo is available in tablet form with a recommended dose of 80 mg once daily. Patients can choose to take it with or without food, but to ensure optimal absorption and efficacy of the drug, patients are advised to take it at the same time every day.

When taking Iqirvo, patients need to be careful to avoid interactions with other drugs. Especially when combined with bile acid sequestrants, it should be used at least 4 hours before or 4 hours after taking Iqirvo, or as long as possible to avoid affecting the absorption and efficacy of Iqirvo.